GDNF fusion polypeptides and methods of use thereof
AssigneeKeros Therapeutics, Inc.
InventorsJasbir S. Seehra, Jennifer Lachey
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods of GDNF fusion polypeptides, wherein the GDNF fusion polypeptides include an Fc domain, an albumin-binding peptide, a fibronectin domain, or a human serum albumin, joined to a GDNF variant either directly or by the way of a linker. The GDNF fusion polypeptides may used to treat metabolic diseases, such as obesity and Type-1 and Type-2 diabetes, and neurological diseases, such as Amyotrophic lateral sclerosis (ALS) and Parkinson's disease.
Claims15
A method of treating and/or preventing a neurological disease in a subject, said method comprising administering to said subject a glial-derived neurotrophic factor (GDNF) fusion polypeptide consisting of the formula A-L-B, wherein
- A is an Fc domain;
- L is a linker;
- and
- B has at least 95% sequence identity to a GDNF variant, wherein the sequence of the GDNF variant is (a) the sequence of amino acids 92-211 of SEQ ID NO:
- 1 or (b) a fragment of the sequence of amino acids 92-211 of SEQ ID NO:
- 1 comprising amino acids 118-211 of SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.